169 related articles for article (PubMed ID: 35305096)
1. ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
Moskovitz M; Dudnik E; Shamai S; Rotenberg Y; Popovich-Hadari N; Wollner M; Zer A; Gottfried M; Mishaeli M; Rosenberg SK; Onn A; Merimsky O; Urban D; Peled N; Maimon N; Bar J
Oncologist; 2022 Feb; 27(1):e76-e84. PubMed ID: 35305096
[TBL] [Abstract][Full Text] [Related]
2. Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
Sheinson D; Wong WB; Wu N; Mansfield AS
Lung Cancer; 2020 May; 143():86-92. PubMed ID: 32276206
[TBL] [Abstract][Full Text] [Related]
3. The overall survival benefit in Chinese ALK
Tian G; Zhao X; Nie J; Dai L; Hu W; Zhang J; Chen X; Han J; Ma X; Wu D; Han S; Long J; Wang Y; Zhang Z; Fang J
J Thorac Dis; 2022 Jun; 14(6):2201-2212. PubMed ID: 35813748
[TBL] [Abstract][Full Text] [Related]
4. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
Tan DS; Thomas M; Kim DW; Szpakowski S; Urban P; Mehra R; Chow LQM; Sharma S; Solomon BJ; Felip E; Camidge DR; Vansteenkiste J; Petruzzelli L; Pantano S; Shaw AT
Lung Cancer; 2022 Jan; 163():7-13. PubMed ID: 34890832
[TBL] [Abstract][Full Text] [Related]
5. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
[TBL] [Abstract][Full Text] [Related]
6. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
7. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.
Zheng N; Zhang Y; Zeng Y; Ma Q; Zhang R; Zhao Q; Lu C; Tian J; Wang Z; Tang H; Luo N; Xiao H; He Y; Wu F; Li L
Target Oncol; 2023 Jul; 18(4):625-636. PubMed ID: 37351800
[TBL] [Abstract][Full Text] [Related]
8. Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
Tabbò F; Passiglia F; Novello S
Curr Oncol Rep; 2021 Jan; 23(1):10. PubMed ID: 33387080
[TBL] [Abstract][Full Text] [Related]
9. ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.
Itchins M; Lau B; Hudson AL; Westman H; Xia CY; Hayes SA; Howell VM; Rodriguez M; Cooper WA; Wei H; Buckland M; Li BT; Li M; Rathi V; Fox SB; Gill AJ; Clarke SJ; Boyer MJ; Pavlakis N
Oncologist; 2020 Aug; 25(8):641-649. PubMed ID: 32558067
[TBL] [Abstract][Full Text] [Related]
10. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Kron A; Alidousty C; Scheffler M; Merkelbach-Bruse S; Seidel D; Riedel R; Ihle MA; Michels S; Nogova L; Fassunke J; Heydt C; Kron F; Ueckeroth F; Serke M; Krüger S; Grohe C; Koschel D; Benedikter J; Kaminsky B; Schaaf B; Braess J; Sebastian M; Kambartel KO; Thomas R; Zander T; Schultheis AM; Büttner R; Wolf J
Ann Oncol; 2018 Oct; 29(10):2068-2075. PubMed ID: 30165392
[TBL] [Abstract][Full Text] [Related]
11. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study.
Gobbini E; Chiari R; Pizzutillo P; Bordi P; Ghilardi L; Pilotto S; Osman G; Cappuzzo F; Cecere F; Riccardi F; Scotti V; Martelli O; Borra G; Maiello E; Rossi A; Graziano P; Gregorc V; Casartelli C; Sergi C; Del Conte A; Delmonte A; Bareggi C; Cortinovis D; Rizzo P; Tabbò F; Rossi G; Bria E; Galetta D; Tiseo M; Di Maio M; Novello S
Clin Transl Oncol; 2020 Mar; 22(3):294-301. PubMed ID: 31630357
[TBL] [Abstract][Full Text] [Related]
13. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
14. Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer.
Ganti AK; Lin CW; Yang E; Wong WB; Ogale S
J Manag Care Spec Pharm; 2022 Mar; 28(3):305-314. PubMed ID: 34913728
[No Abstract] [Full Text] [Related]
15. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
[TBL] [Abstract][Full Text] [Related]
16. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Chow LQM; Barlesi F; Bertino EM; van den Bent MJ; Wakelee HA; Wen PY; Chiu CH; Orlov S; Chiari R; Majem M; McKeage M; Yu CJ; Garrido P; Hurtado FK; Arratia PC; Song Y; Branle F; Shi M; Kim DW
Clin Cancer Res; 2022 Jun; 28(12):2506-2516. PubMed ID: 35091443
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
18. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
Davies J; Martinec M; Coudert M; Delmar P; Crane G
Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
[TBL] [Abstract][Full Text] [Related]
19. Overall Survival of Patients With
Tsimafeyeu I; Moiseenko F; Orlov S; Filippova E; Belonogov A; Nebesnykh A; Khalimov A; Karabina E; Shikina V; Abdelgafur A; Statsenko G; Titova I; Isaichikov D; Makarnyaeva G; Mordovskiy A; Barkovskaya O; Smirnov A; Gikalo M; Savelov N; Kosov D; Imyanitov E; Demidova I; Tjulandin S
J Glob Oncol; 2019 May; 5():1-7. PubMed ID: 31095455
[TBL] [Abstract][Full Text] [Related]
20. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
